Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for March 13, 2013 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



New drug may help those with spinal cord injuries
Spinal cord injuries are serious because they can lead to permanent neurologic impairments in any body system controlled by the affected nerves. This includes not only musculoskeletal systems, but respiratory, urinary and gastrointestinal systems, as well. Fortunately, a new drug is showing promise in possibly restoring the function of these systems. 
x-small text small text medium text large text


    March 13, 2013 /24-7PressRelease/ -- Spinal cord injuries are a significant problem in the U.S. According to the Centers for Disease Control and Prevention, approximately 200,000 in the U.S. are currently living with a spinal cord injury. Each year, anywhere from 12,000 to 20,000 new patients are reported. Experts estimate that the lifetime medical costs associated with a spinal cord injury can run anywhere from $500,000 to $3 million, depending on the severity of the injury.

Spinal cord injuries are serious because they can lead to permanent neurological impairments in any body system controlled by the affected nerves. This includes not only musculoskeletal systems, but respiratory, urinary and gastrointestinal systems, as well. Fortunately, a new drug is showing promise in possibly restoring the function of these systems.

Researchers at Ohio State University studied the effect of an experimental drug, known as LM11A-31, on mice that suffered severe spinal cord injuries. The drug works by blocking the release of a particular protein that after spinal cord injuries damages oligodendrocytes - nerve cells that surround and protect axons, the structures that transmit impulses from the brain to the rest of the body. What makes LM11A-31 particularly interesting is its ability to cross the blood-brain barrier, a naturally occurring partition that protects the brain from potentially harmful blood-borne substances.

In the Ohio State study, researchers began treating mice four hours after their injuries. Treatment lasted a total of 42 days. The mice that received the largest dosages of the drug were eventually able to walk and move their limbs in a coordinated fashion. Further studies are planned to determine whether the drug remains effective if not administered until days or weeks after the injury. Methylprednisolone, the main therapy currently available for reducing the chance of paralysis after a spinal cord injury, must be administered within 24 hours of the initial injury.

Although further study is needed, researchers are hopeful that LM11A-31 will prove an important breakthrough in the treatment of spinal cord injuries.

A personal injury attorney can help

If you or someone you love has suffered a spinal cord injury, traumatic brain injury or other catastrophic injury due to the negligence of another person, contact an experienced personal injury attorney. A knowledgeable personal injury lawyer can assess your case and help you get the fair and adequate compensation you deserve for medical bills, lost wages and pain and suffering. For more information about what a personal injury attorney can do for you, contact a lawyer today.

Article provided by Neufeld, Kleinberg & Pinkert, PA
Visit us at www.neufeldlawfirm.com/


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from FL Web Advantage:

Share This Story
Spread this story with Facebook, Twitter, Linkedin, and more.

Bookmark and Share
Contact Information:
FL Web Advantage

E-Mail: Email us Here
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.